AbCellera Biologics Inc

2026-09-15 23:06; UTC

Abcellera Biologics shares declined in after-market trading, reflecting broader market concerns after a drop in the New York Empire State Manufacturing Index.

2026-09-14 20:08; UTC

Abcellera Biologics is advancing as positive sentiment from Schrödinger's licensing agreement with Tectora Therapeutics influences market activity.

2026-09-11 23:06; UTC

Abcellera Biologics Inc. shares declined in after-market trading, with no specific company news identified. Broader inflation concerns may be influencing market sentiment.

2026-09-10 20:07; UTC

Abcellera Biologics Inc shares are lower today, continuing a decline since Wednesday's close. The stock trades significantly below its 20-day moving average.

2026-09-04 20:08; UTC

Abcellera Biologics Inc shares are lower today amid broader market selling pressure following a strong jobs report, despite earlier gains during the session.

2026-09-03 23:05; UTC

Abcellera Biologics Inc shares are higher in after-market trading, supported by broader market gains amid easing interest rate hike concerns. No specific company news was identified.

2026-09-01 20:08; UTC

Abcellera Biologics Inc shares are lower today amid broader market declines and rising oil prices, which have renewed inflation concerns and interest rate hike expectations.

2026-08-31 23:06; UTC

Abcellera Biologics Inc shares declined in after-market hours, reflecting broader market sentiment influenced by comments on inflation and potential interest rate hikes.

2026-08-28 23:01; UTC

Abcellera Biologics Inc shares are trading lower in after-market hours. No specific company news was identified to explain this movement.

2026-08-26 19:56; UTC

Abcellera Biologics Inc shares are lower today, influenced by declines in the ARK Genomic Revolution ETF and broader genomic sector trends.

2026-08-25 23:06; UTC

Abcellera Biologics Inc. shares declined slightly in after-market trading, despite remaining above their 20-day moving average after recent gains.

2026-08-24 23:36; UTC

Abcellera Biologics Inc. is rising in after-market trading, fueled by a director's $570,000 insider purchase near its 52-week high, indicating insider confidence.

2026-08-21 19:36; UTC

Abcellera Biologics Inc shares are lower today amid broader market pressures. The decline coincides with a drop in U.S. Treasury yields and infrastructure-related assets.

2026-08-20 19:16; UTC

Abcellera shares lower amid broader market pressures, influenced by SPDR ETF.

2026-08-19 23:02; UTC

Abcellera Biologics Inc shares are higher in after-hours trading, reflecting increased investor interest and social media discussions about the stock's potential at $12.20.

2026-08-18 19:56; UTC

Abcellera Biologics Inc shares are lower, influenced by declines in small-cap stocks and rising Treasury yields amid ongoing inflation concerns.

2026-08-17 23:06; UTC

Abcellera Biologics Inc shares are lower in after-market trading, following unusual volatility and a decline in the Russell 2000 Index.

2026-08-14 19:44; UTC

Abcellera Biologics Inc shares are higher today amid increased call option volume and discussions of insider buying, with the stock trading around $10.50.

2026-08-13 19:31; UTC

Abcellera Biologics priced an oversubscribed offering at $9.75 per share, aiming to raise $200 million. Shares are higher since Wednesday's close despite earlier pullback.

2026-08-12 20:02; UTC

Abcellera Biologics has launched a $200 million public offering to support its lead program, while shares are advancing during today's trading session.

2026-08-11 22:51; UTC

Abcellera Biologics announced a $200 million public offering, contributing to a decline in after-market trading amid investor concerns over potential dilution.

2026-08-10 23:06; UTC

Abcellera Biologics reported positive Phase 2 trial results for ABCL635, but shares are lower in after-market hours amid broader market declines.

2026-08-08 00:06; UTC

Abcellera Biologics will release Phase 2 trial results for ABCL635 on August 10, 2026. Shares are trading higher in after-market hours.

2026-08-07 23:21; UTC

Abcellera Biologics will release Phase 2 trial results for ABCL635 on August 10, 2026. Shares are sharply higher in after-market trading amid positive investor sentiment.

2026-08-06 23:06; UTC

Abcellera Biologics Inc. shares are lower in after-market trading, despite earlier reaching a session high and remaining above the 20-day moving average.

2026-08-05 23:02; UTC

Abcellera Biologics shares are lower in after-market hours following disappointing Q2 results, with an EPS of -$0.18 and revenue of $4.1 million.

2026-08-03 19:36; UTC

Abcellera Biologics Inc shares are higher as market sentiment improves following President Trump's cancellation of a military strike on Iran.

2026-07-31 19:33; UTC

Abcellera Biologics Inc is declining during Friday's session, reflecting broader biotech sector weakness amid rising yields and inflation concerns.

2026-07-30 23:41; UTC

Abcellera Biologics shares are lower in after-market trading, reflecting broader market volatility following the Federal Reserve's decision to maintain interest rates.

2026-07-29 23:51; UTC

Abcellera Biologics Inc. shares were roughly flat in after-market hours, with no specific news identified. The stock is down significantly from last month's close.